Patricia Hirano, Senior Vice President, Solino Therapeutics Sells Stock Worth $138,709 By Investing.com

Patricia Hirano, Senior Vice President of Regulatory Affairs at Soleno Therapeutics Inc. (NASDAQ:), recently sold the company’s shares. According to a filing with the Securities and Exchange Commission, Hirano sold a total of 3,030 shares of common stock on January 2 and 3, 2025. The sales were executed at prices ranging from $45.3656 to $46.1764 per share, amounting to an aggregate value of approximately $138,709. The deal took place as the $2 billion market cap company trades near $46 per share, with analysts setting price targets between $67 and $93. according to InvestingPro Through analysis, the stock currently appears overvalued compared to its fair value.

The sales were made to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). Following these transactions, Hirano retains ownership of 105,902 shares in Soleno Therapeutics. InvestingPro The data reveals that the company maintains a strong financial health score of 2.22 (FAIR), with one key strength being that it holds more cash than debt on its balance sheet. Subscribers have access to 6 additional ProTips and a comprehensive professional research report to gain deeper insights into SLNO’s financial position.

In other recent news, Soleno Therapeutics has been the subject of significant developments. Stifel selected Soleno Therapeutics as one of its top biotech picks for 2025, citing upcoming catalysts that could lift the company’s value. The company also noted that Soleno Therapeutics is awaiting a regulatory decision, which could open up new opportunities in rare disease markets. Analysts from Baird, H.C. Wainwright, Oppenheimer and Laidlaw remain bullish on Solino’s product, DCCR, for Prader-Willi syndrome, and it is expected to begin generating revenue by mid-2025.

Other recent developments include changes to the Soleno Board of Directors with the appointment of Matthew Boles as the new leader independent (LON:) Director and Addition: Dawn Carter Beer. The Company also entered into an agreement with Jefferies LLC to sell up to $150 million of its common stock and award performance-based restricted stock units to its employees.

The US Food and Drug Administration (FDA) has extended the review period for Soleno’s New Drug Application (NDA) for DCCR, setting the new target action date of March 27, 2025. Despite the extended review period, analysts from various companies maintain a positive outlook for Soleno, With price targets ranging from $67 to $93.

This article was created with the power of artificial intelligence and reviewed by an editor. For more information, see our terms and conditions.